Savara Inc. (NasdaqGS: SVRA)
Health Care · Biotechnology · US
$5.60
+0.18% today · +78.0% 1Y
Savara Inc. (NasdaqGS: SVRA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.42B and employs 70 people.
Over the last twelve months the share price has gained 78.0%, trading between 2.98 and 7.01.
Tweenvest scores Savara Inc. across four factors: quality 37/100. Its strongest factor is quality.
SVRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.42B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.58
- Dividend yield
- —
- Beta (5Y)
- 0.26
- 52-week high
- $7.01
- 52-week low
- $2.98
- Avg volume (3M)
- —
- Shares outstanding
- 254.14M
- Employees
- 70
- Next earnings
- —
About Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
- ISIN
- US8051111016
- Founded
- 2007
- Listed since
- Apr 28, 2017
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.